Finance

Lists
Outlook: 81.8% bullish·0.0% bearish
Go to analysis
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$110.42
+0.53%
(+0.58) 1D
$111.35
+0.84% (+0.93)
After hours
Closed: Oct 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HALO...
Open
$109.70
High
$112.65
Low
$109.70
Mkt. cap
12.53B
Avg. vol.
2.27M
Volume
1.85M
P/E ratio
32.99
52-wk high
$116.84
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
Open
$109.70
High
$112.65
Low
$109.70
Mkt. cap
12.53B
Avg. vol.
2.27M
Volume
1.85M
P/E ratio
32.99
52-wk high
$116.84
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com
Analyst ratings
Based on 7 analysts giving stock ratings to HALO in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for HALO in the last 3 months.
Highest
Current $110.42
$115.00 (+4.15%)
Average
$100.14 (-9.31%)
Lowest
$78.00 (-29.36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jessica Fye
J.P. Morgan
Hold
Reiterated
$78.00
-29.4%
10/08/2026
David Risinger
Leerink Partners
Buy
Maintained
$110.00
-0.4%
10/07/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$115.00
+4.1%
10/07/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$105.00
-4.9%
08/07/2026
Jason Butler
Citizens JMP
Buy
Maintained
$93.00
-15.8%
08/07/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
$95.00
-14%
08/07/2026
Brendan Smith
TD Cowen
Buy
Reiterated
$105.00
-4.9%
08/07/2026
Corinne Johnson
Goldman Sachs
Sell
Maintained
$57.00
-48.4%
06/14/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
$70.00
-36.6%
05/20/2026
Robert Wasserman
Benchmark Co.
Buy
Maintained
$90.00
-18.5%
02/19/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
$2.28 / $1.82
+25.53%beat
Revenue / Est. (USD)
481.00M / 400.33M
+20.15%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
354.26M
451.77M
376.71M
481.00M
Cost of goods sold
72.49M
110.67M
104.80M
106.84M
Cost of revenue
72.49M
110.67M
104.80M
106.84M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46.09M
63.33M
57.88M
57.00M
Operating expense
63.85M
86.70M
87.39M
86.51M
Total operating expenses
136.34M
197.37M
192.19M
193.34M
Operating income
217.92M
254.40M
184.52M
287.65M
Other non operating income
-
-
-
-
EBT including unusual items
218.96M
-100.85M
180.33M
284.90M
EBT excluding unusual items
218.96M
251.58M
180.30M
284.90M
Income tax expense
43.73M
40.74M
30.28M
54.99M
Effective tax rate
19.97%
-40.40%
16.79%
19.30%
Other operating expenses
-
-
-
-
Net income
175.22M
-141.59M
150.05M
229.91M
Net profit margin
49.46%
-31.34%
39.83%
47.80%
Earnings per share
1.72
-0.24
1.60
2.28
Interest and investment income
5.33M
2.09M
1.29M
2.84M
Interest expense
-4.30M
-4.91M
-5.51M
-5.59M
Net interest expenses
1.04M
-2.82M
-4.22M
-2.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
236.84M
279.08M
215.65M
319.12M
Gain or loss from assets sale
-
2.62M
-
76.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps